$CLGN
CollPlant Biotechnologies Ltd Stock $clgn

$clgn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024030055 Filed on April 04, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$299.0K	$10.96M	$58.00K
YoY Change	415.52%	3565.22%	-81.29%
Cost Of Revenue	$773.0K	$1.125M	$62.00K
YoY Change	1146.77%	181.25%	-88.69%
Gross Profit	-$474.0K	$9.834M	-$4.000K
YoY Change	11750.0%	-9836.63%	-98.32%
Gross Profit Margin	-158.53%	89.73%	-6.9%
Selling, General & Admin	$1.481M	$5.996M	$2.035M
YoY Change	-27.22%	-11.05%	47.79%
% of Gross Profit		60.97%
Research & Development	$3.113M	$10.48M	$2.637M
YoY Change	18.05%	2.23%	20.47%
% of Gross Profit		106.61%
Depreciation & Amortization	$284.0K	$1.102M	$294.0K
YoY Change	-3.4%	2.42%	31.25%
% of Gross Profit		11.21%
Operating Expenses	$4.594M	$16.48M	$4.672M
YoY Change	-1.67%	60.7%	31.02%
Operating Profit	-$5.068M	-$6.646M	-$4.676M
YoY Change	8.38%	-61.13%	22.92%
Interest Expense	$379.0K	$503.0K	$275.0K
YoY Change	37.82%	176.37%	759.38%
% of Operating Profit
Other Income/Expense, Net		-$10.00K
YoY Change		-105.81%
Pretax Income	-$4.689M	-$7.019M	-$4.401M
YoY Change	6.54%	-58.53%	16.68%
Income Tax		$59.99M
% Of Pretax Income
Net Earnings	-$4.689M	-$7.019M	-$4.401M
YoY Change	6.54%	-58.53%	16.68%
Net Earnings / Revenue	-1568.23%	-64.05%	-7587.93%
Basic Earnings Per Share		-$0.62
Diluted Earnings Per Share	-$0.41	-$0.62	-$0.39
COMMON SHARES
Basic Shares Outstanding	11.45M shares	11.39M shares	11.19M shares
Diluted Shares Outstanding		11.39M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.67M	$26.67M	$29.65M
YoY Change	-10.05%	-10.05%	-31.52%
Cash & Equivalents	$26.67M	$26.67M	$29.65M
Short-Term Investments
Other Short-Term Assets	$241.0K	$241.0K	$23.00K
YoY Change	947.83%	947.83%	76.92%
Inventory	$714.0K	$714.0K	$1.430M
Prepaid Expenses
Receivables	$0.00	$0.00	$9.000K
Other Receivables	$393.0K	$393.0K	$543.0K
Total Short-Term Assets	$28.02M	$28.02M	$31.66M
YoY Change	-11.49%	-11.49%	-29.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.859M	$5.859M	$2.966M
YoY Change	97.54%	3.21%	-47.79%
Goodwill
YoY Change
Intangibles	$188.0K		$245.0K
YoY Change	-23.27%		0.82%
Long-Term Investments	$1.000K
YoY Change
Other Assets	$57.00K	$57.00K	$188.0K
YoY Change	-69.68%	-69.68%	-11.74%
Total Long-Term Assets	$6.104M	$6.104M	$6.110M
YoY Change	-0.1%	-0.1%	-0.44%
TOTAL ASSETS
Total Short-Term Assets	$28.02M	$28.02M	$31.66M
Total Long-Term Assets	$6.104M	$6.104M	$6.110M
Total Assets	$34.13M	$34.13M	$37.77M
YoY Change	-9.64%	-9.64%	-26.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.627M	$980.0K	$2.576M
YoY Change	1.98%	-13.5%	149.13%
Accrued Expenses	$624.0K	$2.271M	$529.0K
YoY Change	17.96%	15.16%	1.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$321.0K
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.251M	$3.251M	$3.105M
YoY Change	4.7%	4.7%	3.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.535M	$2.535M	$2.382M
YoY Change	6.42%	6.42%	-22.89%
Total Long-Term Liabilities	$2.535M	$2.535M	$2.382M
YoY Change	6.42%	6.42%	-22.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.251M	$3.251M	$3.105M
Total Long-Term Liabilities	$2.535M	$2.535M	$2.382M
Total Liabilities	$5.786M	$5.786M	$5.487M
YoY Change	5.45%	5.45%	-10.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$96.74M		-$89.72M
YoY Change	7.82%		23.25%
Common Stock	$126.1M		$4.873M
YoY Change	2486.7%		4.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.34M	$28.34M	$32.28M
YoY Change
Total Liabilities & Shareholders Equity	$34.13M	$34.13M	$37.77M
YoY Change	-9.64%	-9.64%	-26.27%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$4.689M	-$7.019M	-$4.401M
YoY Change	6.54%	-58.53%	16.68%
Depreciation, Depletion And Amortization	$284.0K	$1.102M	$294.0K
YoY Change	-3.4%	2.42%	31.25%
Cash From Operating Activities	-$2.345M	-$2.763M	-$3.346M
YoY Change	-29.92%	-79.83%	38.26%
INVESTING ACTIVITIES
Capital Expenditures	$229.0K	$954.0K	$304.0K
YoY Change	-24.67%	-25.12%	-159.96%
Acquisitions
YoY Change
Other Investing Activities	-$143.0K	-$202.0K	$0.00
YoY Change		-100.67%	-100.0%
Cash From Investing Activities	-$372.0K	-$1.156M	-$304.0K
YoY Change	22.37%	-104.0%	-97.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$1.108M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.108M	400.0K
YoY Change	-100.0%	-40.88%	181.69%
NET CHANGE
Cash From Operating Activities	-2.345M	-2.763M	-3.346M
Cash From Investing Activities	-372.0K	-1.156M	-304.0K
Cash From Financing Activities	0.000	1.108M	400.0K
Net Change In Cash	-2.717M	-2.811M	-3.250M
YoY Change	-16.4%	-117.05%	-74.51%
FREE CASH FLOW
Cash From Operating Activities	-$2.345M	-$2.763M	-$3.346M
Capital Expenditures	$229.0K	$954.0K	$304.0K
Free Cash Flow	-$2.574M	-$3.717M	-$3.650M
YoY Change	-29.48%	-75.17%	90.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38370
CY2023	dei	Entity Registrant Name EntityRegistrantName	CollPlant Biotechnologies Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Oppenheimer
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Weizmann Science Park
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Rehovot
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7670104
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, par value NIS 1.50 per share
CY2023	dei	Trading Symbol TradingSymbol	CLGN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11452672	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1281
CY2023	dei	Auditor Name AuditorName	Kost Forer Gabbay & Kasierer
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26674000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29653000	usd
CY2023Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	241000	usd
CY2022Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	23000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	393000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	543000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	714000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1430000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	28022000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	31658000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	57000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	188000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3070000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2711000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2789000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2966000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	188000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	245000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6104000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6110000	usd
CY2023Q4	us-gaap	Assets Assets	34126000	usd
CY2022Q4	us-gaap	Assets Assets	37768000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	980000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1133000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	624000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	529000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1647000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1443000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3251000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3105000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2535000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2382000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2535000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2382000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5786000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5487000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.5
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.5
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11452672	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11452672	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11186481	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11186481	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4982000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4873000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121068000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	118099000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-969000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-969000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96741000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89722000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28340000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32281000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34126000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37768000	usd
CY2023	us-gaap	Revenues Revenues	10959000	usd
CY2022	us-gaap	Revenues Revenues	299000	usd
CY2021	us-gaap	Revenues Revenues	15641000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1991000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	400000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2005000	usd
CY2023	us-gaap	Gross Profit GrossProfit	8968000	usd
CY2022	us-gaap	Gross Profit GrossProfit	-101000	usd
CY2021	us-gaap	Gross Profit GrossProfit	13636000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10484000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10255000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7631000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5996000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6741000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5940000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7512000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17097000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	65000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	493000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7019000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	237000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16925000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.53
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11389168	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11033310	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9968972	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11389168	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11033310	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11966788	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4477000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3205000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32793000	usd
CY2021	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	51000	usd
CY2021	clgn	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	5718000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	299000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1597000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	237000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	45121000	usd
CY2022	clgn	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1700000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	174000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2211000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16925000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32281000	usd
CY2023	clgn	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	744000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	364000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1970000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7019000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28340000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7019000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16925000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	237000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-18000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1102000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1076000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	773000	usd
CY2023	clgn	Accrued Interest AccruedInterest	28000	usd
CY2022	clgn	Accrued Interest AccruedInterest	87000	usd
CY2021	clgn	Accrued Interest AccruedInterest	151000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1937000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2174000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1597000	usd
CY2023	clgn	Effect Of Exchange Rate Changes On Cash And Cash Equivalent EffectOfExchangeRateChangesOnCashAndCashEquivalent	-379000	usd
CY2022	clgn	Effect Of Exchange Rate Changes On Cash And Cash Equivalent EffectOfExchangeRateChangesOnCashAndCashEquivalent	-608000	usd
CY2021	clgn	Effect Of Exchange Rate Changes On Cash And Cash Equivalent EffectOfExchangeRateChangesOnCashAndCashEquivalent	143000	usd
CY2021	clgn	Remeasurement Of Derivatives Liability RemeasurementOfDerivativesLiability	28000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-261000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-560000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-749000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	312000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-181000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-150000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	119000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	185000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-527000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-461000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-400000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-153000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	99000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	236000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-638000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-916000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-337000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	204000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	14000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-464000	usd
CY2022	clgn	Increase Decrease In Deferred Revenues IncreaseDecreaseInDeferredRevenues	32000	usd
CY2021	clgn	Increase Decrease In Deferred Revenues IncreaseDecreaseInDeferredRevenues	175000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2763000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13698000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2501000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	42000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	161000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	954000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1274000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1428000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	50238000	usd
CY2023	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	270000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20000000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	30000000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	68000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	33000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1156000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28922000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31556000	usd
CY2021	clgn	Proceeds From Issuance Of Shares And Warrants Less Issuance Expenses ProceedsFromIssuanceOfSharesAndWarrantsLessIssuanceExpenses	32743000	usd
CY2023	clgn	Proceeds From Exercise Of Options And Warrants Into Shares ProceedsFromExerciseOfOptionsAndWarrantsIntoShares	1108000	usd
CY2022	clgn	Proceeds From Exercise Of Options And Warrants Into Shares ProceedsFromExerciseOfOptionsAndWarrantsIntoShares	1874000	usd
CY2021	clgn	Proceeds From Exercise Of Options And Warrants Into Shares ProceedsFromExerciseOfOptionsAndWarrantsIntoShares	6017000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1108000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1874000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38760000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-379000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-608000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3190000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16490000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9848000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29864000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13374000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3526000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26674000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29864000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13374000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	886000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	219000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	557000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	50000	usd
CY2023	clgn	Capitalization Of Sharebased Compensation To Inventory CapitalizationOfSharebasedCompensationToInventory	33000	usd
CY2022	clgn	Capitalization Of Sharebased Compensation To Inventory CapitalizationOfSharebasedCompensationToInventory	37000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	31000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26674000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29653000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13148000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	23000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	13000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	188000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	213000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26674000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29864000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13374000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - GENERAL</b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Company description</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: justify">CollPlant Biotechnologies Ltd. (the “Company” or “CollPlant”) is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant-based technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. </td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s revenues include income from business collaborators and from sales of (i) bioink products for the development of 3D bioprinting of organs and tissues, (ii) rhCollagen for the medical aesthetics market, and (iii) rhCollagen-based products for tendinopathy and wound care. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company operates mainly through its wholly-owned subsidiary CollPlant Ltd. In November 2021 CollPlant Ltd. established CollPlant Inc., a wholly owned subsidiary in the United States. As of December 31, 2023, CollPlant Inc. has not commenced operation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: justify">For the year ended December 31, 2023, the Company incurred net loss of $7,019 and has an accumulated deficit in the total amount of $96,741. The Company's negative cash flows from operating activities was $2,763. The Company's cash and cash equivalent as of December 31, 2023 totaled $26,674. The Company has sufficient funds to support its operation for more than 12 months following the approval of its consolidated financial statements for the fiscal year ended December 31, 2023.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company expects to incur future net losses and the transition to profitability is dependent upon, among other things, the successful development and commercialization of the Company’s products and product candidates or of the dermal filler product developed by AbbVie, the establishment of contracts for the distribution of new product lines, any of which, or in combination, would contribute to the achievement of a level of revenue adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through existing cash on hand, additional private and/or public offerings of debt or equity securities, additional milestone payments that may be received under the AbbVie Development Agreement, adjustment of operating expenses to meet available cash resources or a combination of the foregoing. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.</p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7019000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96741000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2763000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26674000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>b.</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b>Use of estimates </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. Actual results may differ from those estimates.</p>
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	14000000	usd
CY2023	us-gaap	Depreciation Depreciation	1045000	usd
CY2022	us-gaap	Depreciation Depreciation	1036000	usd
CY2021	us-gaap	Depreciation Depreciation	773000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	775000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	645000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2023Q4	us-gaap	Termination Loans TerminationLoans	14000000	usd
CY2023Q2	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	10000000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	250000	shares
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	173000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	881000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	541000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	549000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	714000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1430000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	866000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	296000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	367000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8835000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8007000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6046000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5041000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2789000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2966000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	646000	usd
CY2023	us-gaap	Variable Lease Payment VariableLeasePayment	52000	usd
CY2022	us-gaap	Variable Lease Payment VariableLeasePayment	24000	usd
CY2021	us-gaap	Variable Lease Payment VariableLeasePayment	12000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	809000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	770000	usd
CY2023	clgn	Schedule Of Supplemental Balance Sheet Information Related To Leases ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases	Supplemental balance sheet information related to leases was as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Operating Leases</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,070</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,711</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Non-current lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,535</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,382</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,911</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5.14 years</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5.7 years</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.46</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.13</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3070000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2711000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	624000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	529000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2535000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2382000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3159000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2911000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M20D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0746	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0713	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	824000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	768000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	664000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	636000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	627000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	303000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3822000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	663000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3159000	usd
CY2023Q4	clgn	Percentage Of Income From Product And Services PercentageOfIncomeFromProductAndServices	0.03	pure
CY2023	us-gaap	Royalty Expense RoyaltyExpense	329000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	9000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	468000	usd
CY2023Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	6987000	usd
CY2023	clgn	Development Agreement Description DevelopmentAgreementDescription	The AbbVie Development Agreement provides that with respect to the Exclusive Products CollPlant shall be entitled to receive up to $50,000 comprised of an upfront cash payment of $14,000, which was paid in February 2021, and up to $36,000 in proceeds upon the achievement of certain development, clinical trial, regulatory and commercial sale milestones. In June 2023, a milestone under the AbbVie Development Agreement was achieved. Such milestone achievement triggered a payment of $10,000 from AbbVie to CollPlant, which was received in July 2023. In addition, CollPlant shall be entitled to a fixed-fee royalty payment (subject to certain adjustments) for each product commercially sold during the applicable royalty term as well as a fee for the supply of rhCollagen to AbbVie. In addition, with respect to the Option Products, CollPlant shall be entitled to receive up to $53,000, as further described below, plus a fixed-fee royalty payment (subject to certain adjustments) for each product commercially sold during the applicable royalty term and a fee for the supply of rhCollagen to AbbVie. The $53,000 in proceeds includes a one-time non-refundable payment of $6,000 upon signing a definitive agreement with regards to the injectable breast implant product; a one-time non-refundable payment of $4,000 for signing a definitive agreement with regards to the photocurable dermal filler product; and up to an additional $43,000 payable upon the achievement of certain clinical trial, regulatory approval and commercial sale milestones. Unless earlier terminated, the AbbVie Development Agreement will continue in effect on a product-by-product and country-by-country basis until the later of (i) the expiration, invalidation or abandonment of the last CollPlant patent covering a product in a particular country, and (ii) 10 years from the first commercial sale of such product in such country. Following expiration (unless earlier terminated), the rights granted to AbbVie in the AbbVie Development Agreement will continue on a non-exclusive, fully paid-up, royalty-free, perpetual and irrevocable basis. The AbbVie Development Agreement may be terminated early by either party for material breach or bankruptcy. In addition, AbbVie may terminate the AbbVie Development Agreement at any time immediately upon written notice to CollPlant if AbbVie reasonably believes that it is not advisable for AbbVie to continue to develop or commercialize the Exclusive Products under the AbbVie Development Agreement as a result of a perceived serious safety issue regarding the use of any Exclusive Product or upon 60 days’ written notice, for any or no reason, with respect to its rights under the AbbVie Development Agreement on an Exclusive Product-by-Exclusive Product or country-by-country basis.
	clgn	Exercised Warrants ExercisedWarrants	992149	shares
	clgn	Return Amount ReturnAmount	3969000	usd
CY2021	clgn	Shares Return SharesReturn	1800000	usd
CY2022	clgn	Shares Return SharesReturn	1700000	usd
CY2023	clgn	Shares Return SharesReturn	744000	usd
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3200000	usd
CY2023	clgn	Description Of Investors DescriptionOfInvestors	On the same date, one of the Company’s investors transferred the Company an amount of $1,000 by way of an equity investment, and the Company issued to the investor 250,000 ADSs representing 250,000 ordinary shares and a warrant to purchase up to 250,000 ADSs representing 250,000 ordinary shares.
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2023	clgn	Investor Shares InvestorShares	250000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
CY2023	clgn	Fair Value Options Granted FairValueOptionsGranted	747000	usd
CY2022	clgn	Fair Value Options Granted FairValueOptionsGranted	3970000	usd
CY2021	clgn	Fair Value Options Granted FairValueOptionsGranted	1094000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1342000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y7M20D
CY2023Q3	us-gaap	Shares Issued SharesIssued	969886	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.39
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	583979	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	579000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Other Expenses OtherExpenses	523	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.32
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.16
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	271000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	221000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	869000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4380000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2802000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3356000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1868749	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M21D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4620000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	158000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.05
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	76441	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.52
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	83156	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	121272	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	8.81
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1745880	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.8
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M28D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	1165000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1151015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.49
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1062000	usd
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1757546	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1157344	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1937000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2174000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1620000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.23	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	59993000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15492000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20105000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1993000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1736000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	230000	usd
CY2023Q4	clgn	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	726000	usd
CY2022Q4	clgn	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	670000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1035000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	349000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23090000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18540000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22466000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	706000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	624000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22466000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3926000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18540000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1052000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	944000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	490000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	446000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	105000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	53000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1647000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1443000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10959000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	299000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15641000	usd
CY2023	us-gaap	Revenues Revenues	10959000	usd
CY2022	us-gaap	Revenues Revenues	299000	usd
CY2021	us-gaap	Revenues Revenues	15641000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	207000	usd
CY2021	clgn	Contract Liability Recognized During The Period ContractLiabilityRecognizedDuringThePeriod	32000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	32000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	207000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	32000	usd
CY2023	clgn	Exchange Rate Differences ExchangeRateDifferences	285000	usd
CY2022	clgn	Exchange Rate Differences ExchangeRateDifferences	115000	usd
CY2021	clgn	Exchange Rate Differences ExchangeRateDifferences	38000	usd
CY2023	clgn	Bank And Other Fees BankAndOtherFees	10000	usd
CY2022	clgn	Bank And Other Fees BankAndOtherFees	10000	usd
CY2021	clgn	Bank And Other Fees BankAndOtherFees	30000	usd
CY2021	clgn	Remeasurement Of Financial Instruments RemeasurementOfFinancialInstruments	28000	usd
CY2022	clgn	Other Financing Expenses OtherFinancingExpenses	24000	usd
CY2021	clgn	Other Financing Expenses OtherFinancingExpenses	7000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	788000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	321000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	219000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	493000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	clgn	Remeasurement Of Derivatives Liability RemeasurementOfDerivativesLiability		usd
CY2022	clgn	Remeasurement Of Derivatives Liability RemeasurementOfDerivativesLiability		usd
CY2023	clgn	Increase Decrease In Deferred Revenues IncreaseDecreaseInDeferredRevenues		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2021	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023	clgn	Proceeds From Issuance Of Shares And Warrants Less Issuance Expenses ProceedsFromIssuanceOfSharesAndWarrantsLessIssuanceExpenses		usd
CY2022	clgn	Proceeds From Issuance Of Shares And Warrants Less Issuance Expenses ProceedsFromIssuanceOfSharesAndWarrantsLessIssuanceExpenses		usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2021	clgn	Capitalization Of Sharebased Compensation To Inventory CapitalizationOfSharebasedCompensationToInventory		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent		usd
CY2023	clgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
CY2023	clgn	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue		usd
CY2023	clgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023	clgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm
CY2023	clgn	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue		usd
CY2023	clgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
CY2023	clgn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023	clgn	Contract Liability Recognized During The Period ContractLiabilityRecognizedDuringThePeriod		usd
CY2022	clgn	Contract Liability Recognized During The Period ContractLiabilityRecognizedDuringThePeriod		usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
CY2023	clgn	Remeasurement Of Financial Instruments RemeasurementOfFinancialInstruments		usd
CY2022	clgn	Remeasurement Of Financial Instruments RemeasurementOfFinancialInstruments		usd
CY2023	clgn	Other Financing Expenses OtherFinancingExpenses		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001631487

Files In Submission

Name	View Source	Status
0001213900-24-030055-index-headers.html	Edgar Link	pending
0001213900-24-030055-index.html	Edgar Link	pending
0001213900-24-030055.txt	Edgar Link	pending
0001213900-24-030055-xbrl.zip	Edgar Link	pending
clgn-20231231.xsd	Edgar Link	pending
ea0202823-20f_collplant.htm	Edgar Link	pending
ea020282301ex12-1_collplant.htm	Edgar Link	pending
ea020282301ex12-2_collplant.htm	Edgar Link	pending
ea020282301ex13-1_collplant.htm	Edgar Link	pending
ea020282301ex13-2_collplant.htm	Edgar Link	pending
ea020282301ex15-1_collplant.htm	Edgar Link	pending
ea020282301ex4-3_collplant.htm	Edgar Link	pending
ea020282301ex4-4_collplant.htm	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
clgn-20231231_cal.xml	Edgar Link	unprocessable
clgn-20231231_def.xml	Edgar Link	unprocessable
clgn-20231231_lab.xml	Edgar Link	unprocessable
clgn-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0202823-20f_collplant_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLGN
CollPlant Biotechnologies Ltd Stock $clgn

2023 Q4 Form 20-F Financial Statement

#000121390024030055 Filed on April 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLGN CollPlant Biotechnologies Ltd Stock $clgn

2023 Q4 Form 20-F Financial Statement

#000121390024030055 Filed on April 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLGN
CollPlant Biotechnologies Ltd Stock $clgn